PMID- 26047375
OWN - NLM
STAT- MEDLINE
DCOM- 20161014
LR  - 20200413
IS  - 1802-9973 (Electronic)
IS  - 0862-8408 (Print)
IS  - 0862-8408 (Linking)
VI  - 64
IP  - 6
DP  - 2015
TI  - Inhibition of soluble epoxide hydrolase does not improve the course of congestive 
      heart failure and the development of renal dysfunction in rats with volume 
      overload induced by aorto-caval fistula.
PG  - 857-73
AB  - The detailed mechanisms determining the course of congestive heart failure (CHF) 
      and associated renal dysfunction remain unclear. In a volume overload model of 
      CHF induced by creation of aorto-caval fistula (ACF) in Hannover Sprague-Dawley 
      (HanSD) rats we explored the putative pathogenetic contribution of 
      epoxyeicosatrienoic acids (EETs), active products of CYP-450 dependent 
      epoxygenase pathway of arachidonic acid metabolism, and compared it with the role 
      of the renin-angiotensin system (RAS). Chronic treatment with 
      cis-4-[4-(3-adamantan-1-yl-ureido) cyclohexyloxy]benzoic acid (c-AUCB, 3 mg/l in 
      drinking water), an inhibitor of soluble epoxide hydrolase (sEH) which normally 
      degrades EETs, increased intrarenal and myocardial EETs to levels observed in 
      sham-operated HanSD rats, but did not improve the survival or renal function 
      impairment. In contrast, chronic angiotensin-converting enzyme inhibition (ACEi, 
      trandolapril, 6 mg/l in drinking water) increased renal blood flow, fractional 
      sodium excretion and markedly improved survival, without affecting left 
      ventricular structure and performance. Hence, renal dysfunction rather than 
      cardiac remodeling determines long-term mortality in advanced stage of CHF due to 
      volume overload. Strong protective actions of ACEi were associated with 
      suppression of the vasoconstrictor/sodium retaining axis and activation of 
      vasodilatory/natriuretic axis of the renin-angiotensin system in the circulating 
      blood and kidney tissue.
FAU - Cervenka, L
AU  - Cervenka L
AD  - Department of Pathophysiology, Second Faculty of Medicine, Charles University, 
      Prague, Czech Republic. luce@medicon.cz.
FAU - Melenovsky, V
AU  - Melenovsky V
FAU - Huskova, Z
AU  - Huskova Z
FAU - Sporkova, A
AU  - Sporkova A
FAU - Burgelova, M
AU  - Burgelova M
FAU - Skaroupkova, P
AU  - Skaroupkova P
FAU - Hwang, S H
AU  - Hwang SH
FAU - Hammock, B D
AU  - Hammock BD
FAU - Imig, J D
AU  - Imig JD
FAU - Sadowski, J
AU  - Sadowski J
LA  - eng
GR  - P01 DK038226/DK/NIDDK NIH HHS/United States
GR  - R01 ES013933/ES/NIEHS NIH HHS/United States
GR  - R01 ES002710/ES/NIEHS NIH HHS/United States
GR  - P42 ES004699/ES/NIEHS NIH HHS/United States
GR  - U24 DK097154/DK/NIDDK NIH HHS/United States
GR  - P42 ES013933/ES/NIEHS NIH HHS/United States
GR  - DK38226/DK/NIDDK NIH HHS/United States
GR  - R01 ES02710/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150605
PL  - Czech Republic
TA  - Physiol Res
JT  - Physiological research
JID - 9112413
RN  - 0 (4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Benzoates)
RN  - 0 (Epoxy Compounds)
RN  - 0 (Peptide Fragments)
RN  - 11128-99-7 (Angiotensin II)
RN  - 8W8T17847W (Urea)
RN  - 9041-90-1 (Angiotensin I)
RN  - EC 3.3.2.- (Epoxide Hydrolases)
RN  - FC398RK06S (8,11,14-Eicosatrienoic Acid)
RN  - IJ3FUK8MOF (angiotensin I (1-7))
SB  - IM
MH  - 8,11,14-Eicosatrienoic Acid/analogs & derivatives/blood/metabolism
MH  - Angiotensin I/blood
MH  - Angiotensin II/blood
MH  - Angiotensin-Converting Enzyme Inhibitors
MH  - Animals
MH  - Benzoates/pharmacology/*therapeutic use
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical
MH  - Epoxide Hydrolases/*antagonists & inhibitors
MH  - Epoxy Compounds/metabolism
MH  - Heart Failure/blood/complications/diagnostic imaging/*drug therapy
MH  - Kidney/metabolism
MH  - Male
MH  - Myocardium/metabolism
MH  - Peptide Fragments/blood
MH  - Random Allocation
MH  - Rats
MH  - Renal Insufficiency/blood/etiology/*prevention & control
MH  - Renin-Angiotensin System/drug effects
MH  - Ultrasonography
MH  - Urea/*analogs & derivatives/pharmacology/therapeutic use
PMC - PMC4984848
MID - NIHMS808494
EDAT- 2015/06/06 06:00
MHDA- 2016/10/16 06:00
PMCR- 2016/08/15
CRDT- 2015/06/06 06:00
PHST- 2015/06/06 06:00 [entrez]
PHST- 2015/06/06 06:00 [pubmed]
PHST- 2016/10/16 06:00 [medline]
PHST- 2016/08/15 00:00 [pmc-release]
AID - 932977 [pii]
AID - 10.33549/physiolres.932977 [doi]
PST - ppublish
SO  - Physiol Res. 2015;64(6):857-73. doi: 10.33549/physiolres.932977. Epub 2015 Jun 5.